Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...
A multidisciplinary approach, including ketamine withdrawal and symptom management, is essential to mitigate long-term ...
Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...
Johnson & Johnson (NYSE:JNJ) announced Tuesday that the U.S. FDA approved a supplemental New Drug Application for its ...
Inquirer on MSN2d
Ketamine a lifeline for severe depression patients in SingaporeKetamine, the controlled drug best known as a horse tranquilizer or party supplement, has in the last four years become a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback